Integrated BioPharma, Inc.

What they do

Integrated BioPharma, Inc. operates in two main business segments: Contract Manufacturing, run by Manhattan Drug Company, Inc., and Other Business Lines. The Contract Manufacturing segment manufactures vitamins and nutritional products for customers, including Life Extension and Herbalife. The company also provides distribution, marketing, and sales services to customers primarily in the United States and Luxembourg.

Revenue drivers

• Contract Manufacturing (MDC) — This segment manufactures vitamins and nutritional supplements and is the primary revenue source, with two major customers (Life Extension and Herbalife) representing approximately 84% of consolidated net sales in fiscal 2025 and 90% in fiscal 2024.
• Other Business Lines — This segment includes customers such as Trusted Influencers Inc., Thermosource Tooling and Manufacturing, Life Technologies, Inc., and Eastern Drayage, contributing to a smaller portion of revenue.
• Customer concentration — The two largest customers in the Contract Manufacturing segment accounted for approximately 90% of total revenue in the nine months ended March 31, 2026, up from 83% in the prior-year period, indicating high reliance on a few accounts.

Recent performance

For the quarter ended March 31, 2026, revenue was $10.1 million, down 27.3% from $13.9 million in the year-ago quarter, and the company reported a net loss of $0.8 million versus net income of $0.6 million in 2025. For the nine months ended March 31, 2026, revenue declined 15.2% to $34.1 million, with an operating loss of $1.8 million versus operating income of $1.4 million in the prior year. Gross profit fell sharply, with a gross loss of $0.3 million for the quarter and gross profit of only $0.8 million for the nine months, compared to $4.1 million in the prior-year period. The company had cash and equivalents of $5.8 million as of March 31, 2026, and total shareholder equity of $19.0 million.

Strategy

Management's stated direction, per the MD&A, focuses on managing customer concentration and mitigating supply chain disruptions. The company has not disclosed a significant pivot in strategy, but it continues to rely on its two major contract manufacturing customers. The recent appointments and commentary from Co-CEOs Riva Sheppard and Christina Kay suggest a focus on addressing revenue declines and cost pressures. There are no explicit long-term strategic investments or new product initiatives disclosed in the provided excerpts.

Risks

• Customer concentration — A significant portion of revenue is concentrated among six customers, with two major contract manufacturing customers representing 84-90% of sales; losing any could have a major adverse impact.
• Revenue decline — Quarterly revenue has declined from $14.2 million in the June 2025 quarter to $10.1 million in the March 2026 quarter, a 27% year-over-year drop in the latest quarter.
• Gross margin pressure — Cost of sales exceeded revenue in the quarter ended March 31, 2026, resulting in a gross loss, partly due to inflation, tariffs, and supply chain delays.
• Supply chain disruptions — Geo-political events and transportation issues have led to delays in receiving raw materials, impacting the ability to meet customer delivery dates.

Outlook

Management commentary in the latest earnings release highlights that revenue from the two largest contract manufacturing customers increased to about 90% of total revenue, indicating a continued dependence. The forward-looking statements caution about risks from competition, regulatory changes, inflation, and tariffs. No specific guidance for future periods is provided in the excerpts.